Skip to content
Review

From glycemic control to neuroprotection: alogliptin as a repurposed candidate for Huntington’s disease

Jul 2026 · Metabolic brain disease · Vol 41 · 0 citations · 113 references
Medicine

TL;DR

This narrative review critically evaluates the available experimental evidence supporting the repurposing potential of Alogliptin for HD and identifies alogliptin as a potent repurposable agent and the necessity to conduct specific experimental and clinical research to determine its effectiveness.

View source

Similar papers

Review Aug 2026

Targeting Klotho Signaling for Neuroprotection in Huntington's Disease: A Comprehensive Review.

INTRODUCTION HD is a hereditary neurodegenerative disease caused by the amplification of the CAG trinucleotide repeat in the HTT gene, leading to a Mutant Huntingtin (mHTT) protein that dysregulates transcription, promotes protein aggregation, induces neuroinflammation, and impairs mitochondrial function. Motor dysfunc...

Shikha Singh, Avnesh Kumar, Falguni Goel et al. · 0 citations
Aug 2026

Astragalin confers coordinated neuroprotection in Parkinson's disease models through modulation of neurotrophic, anti-inflammatory, and synuclein-related pathways.

The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.

Jun Wang, Jie-Yu He, Qin Huang et al. · 0 citations
Review Open access Aug 2026

Neuroprotective Potential of Semaglutide in Parkinson’s Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives

A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...

Dipesh Kumar, Renuka Sahu, Naveen Kumar et al. · 0 citations
Review Aug 2026

Metformin in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications.

As the global burden of neurodegenerative disorders continues to rise with aging populations, there is growing interest in identifying widely available drugs that can be repurposed to target shared metabolic and inflammatory mechanisms underlying these conditions. Increasing evidence suggests that metabolic dysfunction...

Aveline P. Langmead, Breauna A Keane, Jive A Jacob et al. · 0 citations
Aug 2026

Neuroprotective Potential of Terpenoids: A Promising Avenue in Neurology.

Neurodegenerative diseases are progressive disorders characterised by the deterioration of neuronal structure and function, ultimately leading to cognitive deficits and functional impairment. Due to neuroinflammation, oxidative stress, and mitochondrial dysfunction, neurones, which cannot regenerate themselves, are hig...

Nidhi Gairola, Sushmita Uniyal, Jaya Martolia et al. · 0 citations
Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.